heart failure
Conditions
Interventions
Group A1:Healthy participants were administered placebo beverages (10 g of glutamine powder dissolved in 500 mL of lemon water) before the first stress test, and after a 7-day washout period, they pro
Group B1:Healthy participants were administered placebo beverages (500 mL of lemon water) before the first stress test, and after a 7-day washout period, they proceeded to the second stress test. Befo
Group A2:Heart failure patients were administered placebo beverages (10 g of glutamine powder dissolved in 500 mL of lemon water) before the first stress test, and after a 7-day washout period, they p
Group B2:Heart failure patients were administered placebo beverages (500 mL of lemon water) before the first stress test, and after a 7-day washout period, they proceeded to the second stress test. Be
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: I. Healthy Participants: 1. Age >=18 years, inclusive of both males and females (aged between 18 and 60 years old) 2. In good health with no history of cardiovascular diseases 3. Signed informed consent obtained and willing to undergo combined cardiopulmonary exercise testing and exercise stress echocardiography II. Chronic Heart Failure Patients: 1. Age >=18 years 2. Classified as NYHA Functional Class II to III 3. Hospitalized due to heart failure within the past 2 years or demonstrated elevated NT-proBNP or BNP levels within the last 3 months: For sinus rhythm: NT-proBNP >=300 pg/mL; For atrial fibrillation: NT-proBNP >=600 pg/mL 4. Evidence of left ventricular systolic dysfunction or diastolic dysfunction based on echocardiography within the past year: LVEF =50% with at least one of the following indicators of left ventricular diastolic dysfunction: A. Enlarged left atrium: transverse diameter >=38mm. B. Increased left ventricular wall thickness: septum or posterior wall >=11mm, or Left Ventricular Mass Index (LVMI) >=115 g/m² (for males)/ 95 g/m² (for females). C. Elevated left ventricular filling pressure: E/e’ ratio >=13, or mean e’ <9 cm/s 5. Stable chronic heart failure patients who have been under optimal Guideline-Directed Medical Therapy (GDMT) as determined by the investigator for at least 4 weeks, with no changes in heart failure medications (except diuretics) dosage within the last 2 weeks 6. Signed informed consent obtained and willing to undergo combined cardiopulmonary exercise testing and exercise stress echocardiography.
Exclusion criteria
Exclusion criteria: 1. Severe heart failure patients with either LVEF =3 times the Upper Limit of Normal (ULN), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >=3 times ULN. 7. Patients with resting heart rate consistently >90 bpm or 100 beats per minute).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak cardiac output; | — |
Secondary
| Measure | Time frame |
|---|---|
| Peak VO2;Peak heart rate;Peak LVEF; | — |
Countries
China
Contacts
Public ContactJingyi Ren
China-Japan Friendship Hospital
Outcome results
None listed